Molika Ashford

The company hopes that it can persuade urology practices to go with its suite of assays by covering a fuller range of treatment decision points.

Ambitions and timelines diverge, but innovators of expanded panels see broad testing as valuable to current patients and future precision oncology innovation.

Company leaders said that practical steps are being taken to recover from earlier underperformance and support planned growth in NGS and residual disease testing.

The company reported a record number of tests in the quarter led by its skin cancer menu but with notable sales in other test categories. 

The company recently signed a partnership with Sarah Cannon to conduct a 10,000-patient clinical study to further validate its experimental assay.

The company achieved two major milestones this year with the launch of its Guardant Shield test and Medicare reimbursement for its Guardant Reveal test.

The company believes a drop in legacy customer orders should soon resolve while new customers continue to grow as guidelines and attitudes evolve.

Investigators reported that most patients who developed recurrence in their small NSCLC cohort showed a positive ctDNA result by 18 months post-surgery.

With recent response data galvanizing oncologists to expand access to anti-HER2 treatment, digital pathology firm Paige is ramping up efforts to create a companion test.

While the results are from a small study, investigators are working to validate them in larger groups, hoping their method can prove itself for clinical use.